Financial reports
Current reports
8-K
Other Events
19 Jul 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12 Jul 24
8-K
Departure of Directors or Certain Officers
28 Jun 24
8-K
Departure of Directors or Certain Officers
29 May 24
8-K
Departure of Directors or Certain Officers
13 Mar 24
8-K
Other Events
7 Mar 24
8-K
Departure of Directors or Certain Officers
17 Jan 24
8-K
Departure of Directors or Certain Officers
1 Dec 23
8-K
MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2
20 Nov 23
8-K
Departure of Directors or Certain Officers
25 Oct 23
Registration and prospectus
S-1
IPO registration
18 Dec 23
424B3
Prospectus supplement
13 Nov 23
424B3
Prospectus supplement
18 Sep 23
424B4
Prospectus supplement with pricing info
4 Aug 23
424B1
Prospectus with pricing info
4 Aug 23
8-A12B
Registration of securities on exchange
31 Jul 23
S-1/A
IPO registration (amended)
28 Jul 23
S-1/A
IPO registration (amended)
25 Jul 23
S-1/A
IPO registration (amended)
21 Jul 23
S-1/A
IPO registration (amended)
18 Jul 23
Proxies
No filings
Other
EFFECT
Notice of effectiveness
28 Dec 23
CORRESP
Correspondence with SEC
22 Dec 23
UPLOAD
Letter from SEC
22 Dec 23
EFFECT
Notice of effectiveness
3 Aug 23
CERT
Certification of approval for exchange listing
31 Jul 23
CORRESP
Correspondence with SEC
31 Jul 23
CORRESP
Correspondence with SEC
31 Jul 23
CORRESP
Correspondence with SEC
14 Jul 23
CORRESP
Correspondence with SEC
13 Jul 23
UPLOAD
Letter from SEC
10 Jul 23
Ownership
4
Denil Nanji Shekhat
21 Jun 24
4
Erez Aminov
30 May 24
4
Erez Aminov
22 May 24
4
Erez Aminov
27 Mar 24
4
Denil Nanji Shekhat
27 Mar 24
4
Michelle Yanez
27 Mar 24
4
Michael Allen Jerman
27 Mar 24
4
Edward Clouston MacPherson
27 Mar 24
4
Giudice Matthew Paul Del
27 Mar 24
3
Denil Nanji Shekhat
22 Mar 24